| Baseline characteristics of study cohort . | MMF (n = 19) . | EC-MPS (n = 21) . | Total (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 61.1 (28.9) | 55.8 (12.3) | 58.3 (11.0) |
| Gender | |||
| Male | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| Female | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Weight, mean (SD), kg | 79.9 (17.2) | 92.1 (20.0) | 86.1 (19.5) |
| Post-transplant, median (IQR), months | 92 (37–185) | 23 (15.5–51.0) | 43.0 (20.5–131.7) |
| Transplant type | |||
| Kidney | 18 (94.7) | 21 (100.0) | 39 (97.5) |
| Liver | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| Allograft function at randomization | |||
| Creatinine, mean (SD), μmol/L | 120.1 (42.4) | 122.2 (45.3) | 121.2 (43.4) |
| eGFR, mean (SD), mL/min/1.73 m2 | 56.7 (23.9) | 61.7 (24.5) | 59.3 (24.0) |
| Year of transplant | |||
| 1980–89 | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| 1990–99 | 5 (26.3) | 1 (4.8) | 6 (15.0) |
| 2000–09 | 8 (42.1) | 4 (19.0) | 12 (30.0) |
| 2010+ | 5 (26.3) | 16 (76.2) | 21 (52.5) |
| Hospital | |||
| Sir Charles Gairdner Hospital | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| RAH | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Prior PPI | 7 (36.8) | 12 (57.1) | 19 (47.5) |
| CNI type (total daily dose) | |||
| Cyclosporin | 8 (42.1) | 6 (28.6) | 14 (35.0) |
| Dose, median (IQR), mg | 150 (112–200) | 200 (150–200) | 171.4 (42.6) |
| Tacrolimus | 11 (57.9) | 15 (71.4) | 26 (65.0) |
| Dose, median (IQR), mg | 3 (2–4) | 4 (2–7) | 4.2 (3.3) |
| MPA (total daily dose) | |||
| MMF, median (IQR), mg | 1500 (1000–2000) | – | – |
| EC-MPS, median (IQR), mg | – | 1440 (1080–1440) | – |
| Prednisolone (total daily dose) | |||
| Dose, median (IQR), mg | 5 (0–5) | 5 (5–6) | 5.7 (1.3) |
| Randomized drug | |||
| First drug placebo | 9 (47.4) | 11 (52.3) | 20 (50.0) |
| First drug pantoprazole | 10 (52.6) | 10 (47.7) | 20 (50.0) |
| Baseline characteristics of study cohort . | MMF (n = 19) . | EC-MPS (n = 21) . | Total (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 61.1 (28.9) | 55.8 (12.3) | 58.3 (11.0) |
| Gender | |||
| Male | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| Female | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Weight, mean (SD), kg | 79.9 (17.2) | 92.1 (20.0) | 86.1 (19.5) |
| Post-transplant, median (IQR), months | 92 (37–185) | 23 (15.5–51.0) | 43.0 (20.5–131.7) |
| Transplant type | |||
| Kidney | 18 (94.7) | 21 (100.0) | 39 (97.5) |
| Liver | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| Allograft function at randomization | |||
| Creatinine, mean (SD), μmol/L | 120.1 (42.4) | 122.2 (45.3) | 121.2 (43.4) |
| eGFR, mean (SD), mL/min/1.73 m2 | 56.7 (23.9) | 61.7 (24.5) | 59.3 (24.0) |
| Year of transplant | |||
| 1980–89 | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| 1990–99 | 5 (26.3) | 1 (4.8) | 6 (15.0) |
| 2000–09 | 8 (42.1) | 4 (19.0) | 12 (30.0) |
| 2010+ | 5 (26.3) | 16 (76.2) | 21 (52.5) |
| Hospital | |||
| Sir Charles Gairdner Hospital | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| RAH | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Prior PPI | 7 (36.8) | 12 (57.1) | 19 (47.5) |
| CNI type (total daily dose) | |||
| Cyclosporin | 8 (42.1) | 6 (28.6) | 14 (35.0) |
| Dose, median (IQR), mg | 150 (112–200) | 200 (150–200) | 171.4 (42.6) |
| Tacrolimus | 11 (57.9) | 15 (71.4) | 26 (65.0) |
| Dose, median (IQR), mg | 3 (2–4) | 4 (2–7) | 4.2 (3.3) |
| MPA (total daily dose) | |||
| MMF, median (IQR), mg | 1500 (1000–2000) | – | – |
| EC-MPS, median (IQR), mg | – | 1440 (1080–1440) | – |
| Prednisolone (total daily dose) | |||
| Dose, median (IQR), mg | 5 (0–5) | 5 (5–6) | 5.7 (1.3) |
| Randomized drug | |||
| First drug placebo | 9 (47.4) | 11 (52.3) | 20 (50.0) |
| First drug pantoprazole | 10 (52.6) | 10 (47.7) | 20 (50.0) |
Data are expressed as n (%), mean and SD or as median (IQR).
| Baseline characteristics of study cohort . | MMF (n = 19) . | EC-MPS (n = 21) . | Total (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 61.1 (28.9) | 55.8 (12.3) | 58.3 (11.0) |
| Gender | |||
| Male | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| Female | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Weight, mean (SD), kg | 79.9 (17.2) | 92.1 (20.0) | 86.1 (19.5) |
| Post-transplant, median (IQR), months | 92 (37–185) | 23 (15.5–51.0) | 43.0 (20.5–131.7) |
| Transplant type | |||
| Kidney | 18 (94.7) | 21 (100.0) | 39 (97.5) |
| Liver | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| Allograft function at randomization | |||
| Creatinine, mean (SD), μmol/L | 120.1 (42.4) | 122.2 (45.3) | 121.2 (43.4) |
| eGFR, mean (SD), mL/min/1.73 m2 | 56.7 (23.9) | 61.7 (24.5) | 59.3 (24.0) |
| Year of transplant | |||
| 1980–89 | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| 1990–99 | 5 (26.3) | 1 (4.8) | 6 (15.0) |
| 2000–09 | 8 (42.1) | 4 (19.0) | 12 (30.0) |
| 2010+ | 5 (26.3) | 16 (76.2) | 21 (52.5) |
| Hospital | |||
| Sir Charles Gairdner Hospital | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| RAH | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Prior PPI | 7 (36.8) | 12 (57.1) | 19 (47.5) |
| CNI type (total daily dose) | |||
| Cyclosporin | 8 (42.1) | 6 (28.6) | 14 (35.0) |
| Dose, median (IQR), mg | 150 (112–200) | 200 (150–200) | 171.4 (42.6) |
| Tacrolimus | 11 (57.9) | 15 (71.4) | 26 (65.0) |
| Dose, median (IQR), mg | 3 (2–4) | 4 (2–7) | 4.2 (3.3) |
| MPA (total daily dose) | |||
| MMF, median (IQR), mg | 1500 (1000–2000) | – | – |
| EC-MPS, median (IQR), mg | – | 1440 (1080–1440) | – |
| Prednisolone (total daily dose) | |||
| Dose, median (IQR), mg | 5 (0–5) | 5 (5–6) | 5.7 (1.3) |
| Randomized drug | |||
| First drug placebo | 9 (47.4) | 11 (52.3) | 20 (50.0) |
| First drug pantoprazole | 10 (52.6) | 10 (47.7) | 20 (50.0) |
| Baseline characteristics of study cohort . | MMF (n = 19) . | EC-MPS (n = 21) . | Total (n = 40) . |
|---|---|---|---|
| Age, mean (SD) | 61.1 (28.9) | 55.8 (12.3) | 58.3 (11.0) |
| Gender | |||
| Male | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| Female | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Weight, mean (SD), kg | 79.9 (17.2) | 92.1 (20.0) | 86.1 (19.5) |
| Post-transplant, median (IQR), months | 92 (37–185) | 23 (15.5–51.0) | 43.0 (20.5–131.7) |
| Transplant type | |||
| Kidney | 18 (94.7) | 21 (100.0) | 39 (97.5) |
| Liver | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| Allograft function at randomization | |||
| Creatinine, mean (SD), μmol/L | 120.1 (42.4) | 122.2 (45.3) | 121.2 (43.4) |
| eGFR, mean (SD), mL/min/1.73 m2 | 56.7 (23.9) | 61.7 (24.5) | 59.3 (24.0) |
| Year of transplant | |||
| 1980–89 | 1 (5.3) | 0 (0.0) | 1 (2.5) |
| 1990–99 | 5 (26.3) | 1 (4.8) | 6 (15.0) |
| 2000–09 | 8 (42.1) | 4 (19.0) | 12 (30.0) |
| 2010+ | 5 (26.3) | 16 (76.2) | 21 (52.5) |
| Hospital | |||
| Sir Charles Gairdner Hospital | 10 (52.6) | 17 (81.0) | 27 (67.5) |
| RAH | 9 (47.4) | 4 (19.0) | 13 (32.5) |
| Prior PPI | 7 (36.8) | 12 (57.1) | 19 (47.5) |
| CNI type (total daily dose) | |||
| Cyclosporin | 8 (42.1) | 6 (28.6) | 14 (35.0) |
| Dose, median (IQR), mg | 150 (112–200) | 200 (150–200) | 171.4 (42.6) |
| Tacrolimus | 11 (57.9) | 15 (71.4) | 26 (65.0) |
| Dose, median (IQR), mg | 3 (2–4) | 4 (2–7) | 4.2 (3.3) |
| MPA (total daily dose) | |||
| MMF, median (IQR), mg | 1500 (1000–2000) | – | – |
| EC-MPS, median (IQR), mg | – | 1440 (1080–1440) | – |
| Prednisolone (total daily dose) | |||
| Dose, median (IQR), mg | 5 (0–5) | 5 (5–6) | 5.7 (1.3) |
| Randomized drug | |||
| First drug placebo | 9 (47.4) | 11 (52.3) | 20 (50.0) |
| First drug pantoprazole | 10 (52.6) | 10 (47.7) | 20 (50.0) |
Data are expressed as n (%), mean and SD or as median (IQR).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
